GP practices to help identify patients for community COVID drug trials

GPs will help to identify patients eligible for COVID-19 antiviral and antibody treatments as part of trials in the community, the government has announced.

A national study called ‘PANORAMIC’ - run by the University of Oxford with GP hubs - will see GP practices and other healthcare providers recruit up to 10,600 patients aged over 50, or aged 18 to 49 and at risk of serious illness from COVID-19 to take the treatment molnupiravir at home after receiving a positive PCR test.

The study, which launches today, will see GPs identify potential participants, invite them to take part and support their participation. Participants who test positive for coronavirus and start treatment will be asked to complete a daily diary for 28 days, or have weekly calls to discuss their symptoms.

Experts hope to gather further data on the potential benefits of the treatments for vaccinated patients, to inform rollout plans for the antiviral next year. Results of the trial are anticipated in early 2022.

COVID treatments

Patients at the highest risk, including the immunocompromised, people with cancer, people with Down’s syndrome, or those who test positive for coronavirus will be able to access either molnupiravir or the novel monoclonal antibody Ronapreve outside of the study from 16 December.

GPonline reported in November that GPs could be able to prescribe molnupiravir to treat COVID-19 after it was approved by the UK medicines regulator - with trials showing it reduced infected patients' risk of hospitalisation or death.

PANORAMIC has been designed as a ‘platform clinical trial’, meaning it can rapidly evaluate several antiviral treatments over time that could help clinically vulnerable people with COVID-19 recover sooner, prevent the need for hospital admission and so ease the burden on the NHS.

Those contacted by the study are urged to enroll urgently to ensure that they have the opportunity to access antiviral treatments within the first five days of COVID-19 symptoms following PCR test, when the drug is most effective.

GP practices

Professor Chris Butler, co-chief investigator of PANORAMIC and professor of primary care at the University of Oxford’s Nuffield Department of Primary Care Health Sciences, said: ‘It is early on in the illness, when people are still being cared for in the community, that treatments for COVID-19 could have their greatest benefit.

‘So far, a lot of the research has focussed on finding out if well-known drugs can be repurposed to treat COVID-19.  This new trial will test whether exciting, new antiviral treatments that are more specific to COVID-19 help people in the community recover faster and reduce the need for treatment in hospital.

‘All community health and social care providers will be able to link people with the trial; everyone who is eligible across the UK will be able to join PANORAMIC, and many will be able to do so from their own homes by participating online with support from their GPs and study team, with medicines sent directly to them at home.’

People receiving the treatments outside of the trial will be assessed over the phone by an expert clinician from an NHS COVID Medicines Delivery Unit (CMDU), who will review and discuss with the patient what the most appropriate treatment would be for them.

High risk groups

Those being prescribed a monoclonal antibody treatment will be invited to attend the CMDU, while those receiving molnupiravir can have someone collect it for them or have it delivered to their home.

Patients who feel they may be eligible for the treatment but have not been contacted are invited to contact their GP or consultant to discuss whether they should be in the highest risk group. They will be provided with further information on next steps if appropriate.

The MHRA approved the second COVID-19 treatment sotrovimab last week, after trials found it reduced risk of hospitalisation and death by 79% in high-risk adults with symptomatic COVID-19 infection.

The treatment molnupiravir can be taken orally in pill form and is effective at reducing risk of hospitalisation and death in people with mild to moderate infection with the virus who are at high risk of developing severe disease.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Follow Us:

Just published

NHS prescription and packet of pills

GPs can now prescribe flu antivirals on the NHS

GPs and other prescribers are now able to issue NHS prescriptions for antivirals...

GP sign

Prevention set to be key battleground for 2024 GP contract

Negotiations on a new GP contract from 2024/25 will need to 'align closely' with...

Talking General Practice logo

Podcast: What makes a strong PCN and how will integrated care systems affect networks?

Talking General Practice speaks to GP and PCN clinical director Professor Aruna Garcea,...


GP core funding rise outstripped by staff pay awards under five-year contract

Staff pay awards have outstripped increases in core GP practice funding between 2019/20...

BMA sign

Fifth of GP time spent on non-medical work as NHS absorbs cost of 'government failure'

Doctors are 'picking up the pieces of government failures' as the cost-of-living...


How the five fundamentals of COPD care can help GPs support patients

GP Dr Andrew Whittamore, clinical lead at Asthma + Lung UK, explains NICE’s five...